N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
Disclosed in the present application is a crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate, wherein the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate is crystal Form I, and the crystal Form I has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2θ° of 7.83±0.2, 26.64±0.2 and 18.89±0.2. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate provided by the present application has four crystal forms, has high solubility and strong stability, can deliver drugs more effectively, increases the permeability of the delivered drugs in the gastrointestinal tract, and is beneficial to the preparation of oral preparations, such that preventive and/or therapeutic drugs can be better delivered into the body to achieve the effect of improving the bioavailability.
1. A crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate, wherein the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate is crystal Form I, and the crystal Form I has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2θ° of 7.83±0.2, 26.64±0.2, and 18.89±0.2.
2. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate according to claim 1 , wherein the crystal Form I further has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2θ° of 5.24±0.2 or 21.59±0.2.
3. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate according to claim 2 , wherein the crystal Form I further has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2θ° of 13.02±0.2 or 24.29±0.2.
4. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate according to claim 3 , wherein the crystal Form I further has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2θ° of any one of 6.61±0.2, 10.43±0.2, 31.63±0.2, and 37.00±0.2.
5. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate according to claim 1 , wherein the X-ray powder diffraction pattern of the crystal Form I is shown as FIG. 1 .
6. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate according to claim 1 , wherein the melting point of the crystal Form I is 163.1° C.
7. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate according to claim 1 , wherein the adsorption water removal temperature of the crystal Form I is 83.6° C.
8. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate according to claim 1 , wherein the crystal Form I loses 3.0% of weight at 140° C.
9. A method of preparing a crystal Form I of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate, wherein the method comprises the steps of:
adding an organic solvent into a reaction vessel and stirring, then adding N-[8-(2-hydroxybenzoyl) amino] octanoic acid and stirring evenly, adding potassium hydroxide solution dropwise, after the dropwise addition, concentrating to obtain the crude product;
adding an organic solvent to the crude product to obtain a filter cake after beating and suction filtration, rinsing the filter cake and placing it in a drying oven for drying to obtain the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate.
10. The method according to claim 9 , wherein the filter cake is rinsed and then put into a drying oven for drying to obtain crystal Form I of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate, wherein the drying temperature is 60-100° C., and the drying time is 30-40 hours.
11. The method according to claim 9 , wherein the organic solvent is isopropanol or acetone; and
the concentration of the potassium hydroxide solution is 40-90%.
12. The method according to claim 9 , wherein, after adding N-[8-(2-hydroxybenzoyl) amino] octanoic acid, the temperature of the system is raised to 48° C. or above, then potassium hydroxide solution is added dropwise, and, after the dropwise addition, the temperature is maintained to react for 0.5-2 hours;
wherein the N-[8-(2-hydroxybenzoyl) amino] octanoic acid and potassium hydroxide solution is added in a molar ratio of 1:1; and
the beating time after adding the organic solvent to the crude product is 0.5-1.5 hours.
13. A method of preparing a crystal Form I of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate, wherein the crystal forms of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate other than crystal Form I are heated to at least 75° C. to produce crystal Form I;
the crystal forms of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate other than crystal Form I are at least one or more of crystal Form II, crystal Form III and crystal Form IV; and
the crystal Forms of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate, other than crystal Form I, are heated to 75° C. or above under nitrogen protection to produce crystal Form I of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate.
14. The method according to claim 13 , wherein the crystal Form II of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate is heated to 140° C. under nitrogen protection to produce crystal Form I of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate.
15. The method according to claim 13 , wherein the crystal Form IV of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate is heated to 110° C. under nitrogen protection to produce crystal Form I of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate.
16. A method of preparing crystal Form I of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate, wherein the crystal forms of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate, other than crystal Form I, are lyophilized to produce crystal Form I;
the crystal forms of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate, other than crystal Form I, are at least one or more of crystal Form II, crystal Form III and crystal Form IV; and
the crystal Form I is crystal Form I of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate according to claim 1 .
17. A pharmaceutical composition comprising a crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate;
wherein the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate is crystal Form I.
18. The pharmaceutical composition according to claim 17 , further comprising a preventive and/or therapeutic drug;
wherein, in the pharmaceutical composition, the weight ratio of the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl) amino] octanoate to the preventive and/or therapeutic drug is (20-60): 1.
19. The pharmaceutical composition according to claim 18 , wherein the preventive and/or therapeutic drug is one or more of glucagon-like peptide-1, insulin, PYY, human amylin, heparin, human growth hormone, interferon, monoclonal antibody, protease inhibitor, and thrombopoietin.